Featured Research

from universities, journals, and other organizations

Gene profiling technique to accelerate stem cell therapies for eye diseases

Date:
July 16, 2014
Source:
NIH, National Eye Institute (NEI)
Summary:
A technique that will speed up the production of stem-cell derived tissues has been developed by researchers. The technique will help the researchers in their efforts to use patients’ skin cells to regenerate retinal pigment epithelium (RPE) -— a tissue in the back of the eye that is affected in several blinding eye diseases. It will also help the scientists search for drugs for personalized treatments.

Retinal pigment epithelium derived from induced pluripotent stem cells.
Credit: Dr. Kapil Bharti, National Eye Institute

Researchers at the National Institutes of Health have developed a technique that will speed up the production of stem-cell derived tissues. The method simultaneously measures the expression of multiple genes, allowing scientists to quickly characterize cells according to their function and stage of development. The technique will help the researchers in their efforts to use patients' skin cells to regenerate retinal pigment epithelium (RPE) -- a tissue in the back of the eye that is affected in several blinding eye diseases. It will also help the scientists search for drugs for personalized treatments.

Related Articles


"Progress in stem cell-based therapies has been limited by our capacity to authenticate cells and tissues," said Kapil Bharti, Ph.D., a Stadtman Investigator in the Unit on Ocular and Stem Cell Translational Research at the National Eye Institute (NEI), a part of NIH. "This assay expands that capacity and streamlines the process."

The assay was described in a recent issue of Stem Cells Translational Medicine.

The RPE is a single layer of cells that lies adjacent to the retina, where the light-sensitive photoreceptors commonly called rods and cones are located. The RPE supports photoreceptor function. Several diseases cause the RPE to break down, which in turn leads to the loss of photoreceptors and vision.

The stem cells Dr. Bharti is using to make RPE are induced pluripotent (iPS) stem cells, which are produced by reverting mature cells to an immature state, akin to embryonic stem cells. iPS cells can be derived from a patient's skin or blood cells, coaxed into other cell types (such as neurons or muscle), and in theory, re-implanted without causing immune rejection.

To verify the identity of RPE made from iPS cells, scientists use microscopy to ensure the tissue looks like RPE and physiological assays to ensure the tissue behaves like RPE. They also use a technique called quantitative RT-PCR to measure the expression of genes that indicate ongoing cell development and function. For example, expression of the gene SOX2 is much higher in iPS cells than mature RPE.

But quantitative RT-PCR only permits the simultaneous measurement of a few genes per sample. Dr. Bharti teamed up with Marc Ferrer, Ph.D., of NIH's National Center for Advancing Translational Sciences (NCATS) to develop a multiplex assay -- a method for simultaneously measuring multiple genes per RPE sample in a highly automated fashion. The assay is based on a commercially available platform from the biotech company Affymetrix. In the assay, tiny snippets of DNA tethered to beads are used to capture RNA molecules -- created when genes are expressed by cells in the RPE sample. Once captured, the RNA from distinct genes is labeled with a fluorescent tag.

Starting with cells from a skin biopsy, the researchers generated iPS-derived RPE and then measured the expression of eight genes that are markers of development, function, and disease. They measured RNA levels of each gene one at a time using quantitative RT-PCR and then all genes simultaneously using the multiplex assay. When compared, the results correlated.

The researchers then used the multiplex assay to compare gene expression of iPS-derived RPE to iPS cells and to RPE cells cultured from an eye. Compared to iPS cells, iPS-derived RPE expressed lower levels of SOX2 and higher levels of the RPE-specific genes PAX6, RPE65, RDH5, TRPM1, and BEST1. Compared to cultured RPE, iPS-derived RPE expressed higher levels of SOX2 and PAX6 -- both developmental markers -- but lower levels of the RPE-specific genes, suggesting a relatively immature state.

"This report demonstrates proof of principle that relevant gene expression changes in iPS-derived RPE can be measured with confidence using a fully automated, high-throughput assay," said Dr. Bharti. Once they had the assay working, the researchers halved its cost and increased its output by using fewer cells and smaller solution volumes.

Dr. Bharti and colleagues at NEI are collaborating with the New York Stem Cell Foundation to produce iPS cell lines from patients with age-related macular degeneration (AMD) -- the most common cause of vision loss among older Americans -- and from other patients with rare hereditary eye diseases. These iPS cell lines will be available to the entire scientific community through a central repository. Dr. Bharti will generate RPE from these cell lines to study AMD.

The multiplex assay will be used as a quality check on the cells, and for screening the effects of potentially therapeutic compounds. It will also help refine production of RPE for cell therapy. With a Therapeutic Challenge Award from the NIH Common Fund, Dr. Bharti is leading efforts toward a clinical trial of iPS-derived RPE for AMD. The trial will test whether replacing damaged RPE with RPE from patients' own cells can prevent AMD-related vision loss.


Story Source:

The above story is based on materials provided by NIH, National Eye Institute (NEI). Note: Materials may be edited for content and length.


Journal Reference:

  1. M. Ferrer, B. Corneo, J. Davis, Q. Wan, K. J. Miyagishima, R. King, A. Maminishkis, J. Marugan, R. Sharma, M. Shure, S. Temple, S. Miller, K. Bharti. A Multiplex High-Throughput Gene Expression Assay to Simultaneously Detect Disease and Functional Markers in Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium. Stem Cells Translational Medicine, 2014; DOI: 10.5966/sctm.2013-0192

Cite This Page:

NIH, National Eye Institute (NEI). "Gene profiling technique to accelerate stem cell therapies for eye diseases." ScienceDaily. ScienceDaily, 16 July 2014. <www.sciencedaily.com/releases/2014/07/140716123413.htm>.
NIH, National Eye Institute (NEI). (2014, July 16). Gene profiling technique to accelerate stem cell therapies for eye diseases. ScienceDaily. Retrieved February 27, 2015 from www.sciencedaily.com/releases/2014/07/140716123413.htm
NIH, National Eye Institute (NEI). "Gene profiling technique to accelerate stem cell therapies for eye diseases." ScienceDaily. www.sciencedaily.com/releases/2014/07/140716123413.htm (accessed February 27, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, February 27, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sleeping Too Much Or Too Little Might Increase Stroke Risk

Sleeping Too Much Or Too Little Might Increase Stroke Risk

Newsy (Feb. 26, 2015) People who sleep more than eight hours per night are 45 percent more likely to have a stroke, according to a University of Cambridge study. Video provided by Newsy
Powered by NewsLook.com
London Show Dissects History of Forensic Science

London Show Dissects History of Forensic Science

AFP (Feb. 25, 2015) Forensic science, which has fascinated generations with its unravelling of gruesome crime mysteries, is being put under the microscope in an exhibition of real criminal investigations in London. Duration: 00:53 Video provided by AFP
Powered by NewsLook.com
Michigan Couple Celebrates Identical Triplets

Michigan Couple Celebrates Identical Triplets

AP (Feb. 25, 2015) A suburban Detroit couple who have two older children are adjusting to life after becoming parents to identical triplets _ a multiple birth a doctor calls rare. (Feb. 25) Video provided by AP
Powered by NewsLook.com
Mayor Says District of Columbia to Go Ahead With Pot Legalization

Mayor Says District of Columbia to Go Ahead With Pot Legalization

Reuters - News Video Online (Feb. 25, 2015) Washington&apos;s mayor says the District of Columbia will move forward with marijuana legalization, despite pushback from Congress. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins